Share
6,848 Posts.
lightbulb Created with Sketch. 2536
clock Created with Sketch. 01/10/21
11:10
Share
Originally posted by RBx
↑
Impact of COVID-19 on clinical trials and clinical research: A systematic review (nih.gov)
Conclusion The COVID-19 pandemic has resulted in a series of public health policies that have crippled the healthcare systems of many countries. This situation hugely impacted the study participants, care providers, researchers, trial sponsors, and research organizations concerning clinical trials. This pandemic has a substantial impact on the trial sites as they experience difficulty in the continuation of trial activities which eventually hampers the progress of the trial and delays study timelines. Most sites are struggling due to delayed subject enrollment, shortfalls in monitoring, and risks of compromised data integrity, and this situation has negatively impacted the initiation of future trials as well ...
Meanwhile, Noxopharm and its collaborators continue with their voyage of discovery, as witnessed by the publication yesterday of a 92-page patent application that included 18 pages of astounding pre-clinical data.
Interestingly, the Inflammation application mentions the potential for nasal, oral, intravenous or rectal delivery; and an as-yet-unpublished application is entitled "Improved Isoflavone Formulation"; so it looks like we have more exciting news on the way.
Expand
Covid has been with us for 20 months. Any study start dates listed by any company would be well aware of the environment and realistic timelines. Nox is famous for late starts and missed timelines and you know that for a fact.
